T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
Main Street Capital
MAIN
$5.47B
| $38.4M | 0.01% |
933,565
-49,571
| -5% | -$1.97M |
|
977
Q32 Bio
QTTB
$458M
| $38.3M | 0.01% |
108,732
+49,720
| +84% | +$19.5M |
|
978
First Bancorp
FBNC
$2.72B
| $38.3M | 0.01% |
1,051,108
-6,779
| -0.6% | -$248K |
|
|
ODT
979
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $38.2M | 0.01% |
1,042,446
+672,721
| +182% | +$16.1M |
|
980
Medpace
MEDP
$16.7B
| $37.9M | 0.01% |
578,979
+283,143
| +96% | +$16.3M |
|
981
PDF Solutions
PDFS
$2.19B
| $37.5M | 0.01% |
2,861,709
-97,894
| -3% | -$1.26M |
|
982
Nexstar Media Group
NXST
$5.7B
| $37.4M | 0.01% |
369,856
+133,739
| +57% | +$14.4M |
|
983
Krystal Biotech
KRYS
$9.85B
| $37.3M | 0.01% |
927,079
+622,959
| +205% | +$20.4M |
|
984
Stoneridge
SRI
$197M
| $37.3M | 0.01% |
1,181,223
+1,166,672
| +8,018% | +$34.5M |
|
|
ELME
985
Elme Communities
ELME
$144M
| $36.8M | 0.01% |
1,377,484
-986,742
| -42% | -$27.3M |
|
986
Ameris Bancorp
ABCB
$5.94B
| $36.8M | 0.01% |
939,198
-181
| -0% | -$6.61K |
|
|
CBIO
987
Crescent Biopharma
CBIO
$610M
| $36.3M | 0.01% |
30,444
-3,798
| -11% | -$4.54M |
|
|
TPTX
988
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $36.2M | 0.01% |
+890,050
| New | +$31.7M |
|
|
ECOL
989
DELISTED
US Ecology, Inc.
ECOL
| $36.2M | 0.01% |
607,911
-15,168
| -2% | -$894K |
|
990
Brown-Forman Class B
BF.B
$12.8B
| $36.2M | 0.01% |
652,910
+2,220
| +0.3% | +$118K |
|
991
Hilton Grand Vacations
HGV
$3.49B
| $36.1M | 0.01% |
1,133,442
+3,583
| +0.3% | +$107K |
|
992
NetEase
NTES
$79.5B
| $35.8M | 0.01% |
699,560
-282,630
| -29% | -$15M |
|
993
Equity Bancshares
EQBK
$1.06B
| $35.7M | 0.01% |
1,337,262
+72,385
| +6% | +$1.93M |
|
994
Luxfer Holdings
LXFR
$457M
| $35.5M | 0.01% |
1,446,689
-1,017,739
| -41% | -$24.7M |
|
|
XYZ
995
Block Inc
XYZ
$47B
| $35.3M | 0.01% |
486,962
-132,653
| -21% | -$9.27M |
|
996
Milestone Pharmaceuticals
MIST
$141M
| $35.3M | 0.01% |
+1,299,946
| New | +$26.8M |
|
997
Healthpeak Properties
DOC
$14.2B
| $35.3M | 0.01% |
1,102,557
+253,314
| +30% | +$7.87M |
|
|
CYBR
998
DELISTED
CyberArk
CYBR
| $35.2M | ﹤0.01% |
275,525
-455,610
| -62% | -$57.7M |
|
999
ScottsMiracle-Gro
SMG
$3.62B
| $35M | ﹤0.01% |
355,565
-3,275
| -0.9% | -$291K |
|
1000
Quanterix
QTRX
$139M
| $34.8M | ﹤0.01% |
1,030,830
+37,869
| +4% | +$980K |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.